Secukinumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Secukinumab" in French language version.

refsWebsite

Global rank French rank

4^th place

12^th place

2,374^th place

298^th place

222^nd place

129^th place

1,226^th place

347^th place

1sciencedirect.com

149^th place

80^th place

2,393^rd place

506^th place

57^th place

4^th place

2^nd place

3^rd place

bmj.com

ard.bmj.com

(en) Genovese MC, Durez P, Richards HB et al. « Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study » Ann Rheum Dis, 2013;72:863-869.

gut.bmj.com

(en) Hueber W, Sands BE, Lewitzky S et al. « Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial » Gut, 2012;61:1693-1700

doi.org

dx.doi.org

Kexin Jiang, Yuheng Jia, Li Chen et Fangyang Huang, « Association of IL-17 Inhibitors with Hypertension in Patients with Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials », Journal of Cardiovascular Pharmacology,‎ 27 février 2024 (ISSN 1533-4023, PMID 38417026, DOI 10.1097/FJC.0000000000001547, lire en ligne, consulté le 4 mars 2024)

issn.org

portal.issn.org

Kexin Jiang, Yuheng Jia, Li Chen et Fangyang Huang, « Association of IL-17 Inhibitors with Hypertension in Patients with Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials », Journal of Cardiovascular Pharmacology,‎ 27 février 2024 (ISSN 1533-4023, PMID 38417026, DOI 10.1097/FJC.0000000000001547, lire en ligne, consulté le 4 mars 2024)

nejm.org

Baeten D, Sieper J, Braun J et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis, N Engl J Med2015; 373:2534-2548
(en) Langley RG, Elewski BE, Lebwohl M et al. « Secukinumab in plaque psoriasis — Results of two phase 3 trials » N Engl J Med, 2014;371:326-338.

nih.gov

ncbi.nlm.nih.gov

(en) Hueber W, Patel DD, Dryja T et al. « Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis » Sci Transl Med, 2010;2:52ra72.
Kexin Jiang, Yuheng Jia, Li Chen et Fangyang Huang, « Association of IL-17 Inhibitors with Hypertension in Patients with Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials », Journal of Cardiovascular Pharmacology,‎ 27 février 2024 (ISSN 1533-4023, PMID 38417026, DOI 10.1097/FJC.0000000000001547, lire en ligne, consulté le 4 mars 2024)

pubmed.ncbi.nlm.nih.gov

Kexin Jiang, Yuheng Jia, Li Chen et Fangyang Huang, « Association of IL-17 Inhibitors with Hypertension in Patients with Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials », Journal of Cardiovascular Pharmacology,‎ 27 février 2024 (ISSN 1533-4023, PMID 38417026, DOI 10.1097/FJC.0000000000001547, lire en ligne, consulté le 4 mars 2024)

sciencedirect.com

McInnes IB, Mease PJ, Kirkham B et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2015;386:1137–1146

thelancet.com

McInnes IB, Behrens F, Mease PJ et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled phase 3b trial, Lancet, 2020;395:1496-1505

wiley.com

onlinelibrary.wiley.com

(en) Rich P, Sigurgeirsson B, Thaci D et al. « Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study » Br J Dermatol, 2013;168:402-411.
(en) Papp KA, Langley RG, Sigurgeirsson B et al. « Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study » Br J Dermatol, 2013;168:412-421.